Brilinta contains ticagrelor, a reversible P2Y12 platelet receptor inhibitor that helps prevent blood platelets from sticking together and forming harmful clots. It is commonly prescribed with low-dose aspirin following acute coronary syndrome or certain coronary interventions.
Brilinta helps reduce the risk of recurrent heart attack, stroke, and cardiovascular death in eligible patients. Treatment duration and dosing should follow current clinical guidelines and the advice of the prescribing healthcare professional.
Uses
- Acute coronary syndrome (ACS)
- Prevention of thrombotic cardiovascular events
- Patients undergoing percutaneous coronary intervention (PCI)
Active Ingredients
- Ticagrelor 90 mg
How to Take
- Take exactly as prescribed.
- Usually taken twice daily together with low-dose aspirin unless otherwise directed.
- May be taken with or without food.
Precautions
- Prescription-only medicine.
- Increases the risk of bleeding.
- Inform healthcare providers before surgery or dental procedures.
- Avoid use in patients with active bleeding or a history of intracranial haemorrhage.
